Taysha gene therapies to participate in the oppenheimer 32nd annual virtual healthcare conference

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in two fireside chats at the oppenheimer 32nd annual virtual healthcare conference on monday, march 14, 2022, and tuesday, march 15, 2022. a webcast of bot
TSHA Ratings Summary
TSHA Quant Ranking